Quality Control Guidelines for Clinical-Grade Human Induced Pluripotent Stem Cell Lines
In this talk, Andrew Gaffney is joined by Stephen Sullivan from the Global Alliance for iPSC Therapies (GAiT) to discuss the importance of iPSC characterization as well as risks and mitigation strategies involved in creating a cell therapy.
About the Speakers
Dr. Stephen Sullivan is a program manager at the Global Alliance for iPSC Therapies (GAiT). Since 2017, Dr Sullivan has overseen operations at GAiT, supporting implementation and clinical application of therapies derived from pluripotent stem cells for the benefit of patients globally.
Dr. Andrew Gaffney completed his PhD in Pediatric Oncology from the University of Leeds, UK, where he successfully established a human embryonic stem cell disease model of Ewing’s sarcoma. Currently, Andrew works closely with renowned stem cell scientists in both industry and academia to monitor the requirements needed for establishing successful hPSC-based disease models, drug screens, and cell therapy applications, as part of STEMCELL’s Strategic Alliances.
Request Pricing
Thank you for your interest in this product. Please provide us with your contact information and your local representative will contact you with a customized quote. Where appropriate, they can also assist you with a(n):
Estimated delivery time for your area
Product sample or exclusive offer
In-lab demonstration
Related Multimedia
-
Considerations for High-Efficiency Genome Editing of Human Pluripotent Stem Cells
Publish Date: May 29, 2020 -
Qualification of Ancillary/Raw Materials for Clinical Use
Publish Date: June 20, 2018 -
Improving Reproducibility of Your hPSC Research by Generating a High-Quality Cell Bank
Publish Date: May 27, 2020
Explore Our Products
-
cGMP, stabilized feeder-free maintenance medium for human ES and iPS cells -
Animal origin-free suspension culture medium for human ES and iPS cells -
cGMP, feeder-free maintenance medium for human ES and iPS cells -
qPCR analysis kit for detecting the majority of karyotypic abnormalities reported in human ES and iPS cells
